Literature DB >> 15900599

Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma.

Emina Torlakovic1, Wolfgang Lilleby, Aasmund Berner, Goran Torlakovic, Rajni Chibbar, Torbjørn Furre, Sophie D Fosså.   

Abstract

The expression, distribution and the role of steroid receptors in benign and malignant untreated prostate tissues is well recognized, however, the status of steroid receptors in prostate after radiotherapy (RT) for adenocarcinoma has not yet been studied fully. Immunohistochemical evaluation of androgen receptor (AR), estrogen receptor-alpha (ER-alpha), estrogen receptor-beta (ER-beta), and progesterone receptor (PR) was carried out in prostate needle biopsies obtained before and after radiotherapy from 60 patients with adenocarcinoma. The ER-beta transcripts were also studied by RT-PCR in LNCaP prostate carcinoma cell line before and 24 hr after gamma-irradiation at 0.5 Gy and 8.0 Gy. Significantly higher level of ER-beta expression was found in post-radiation samples of prostate adenocarcinoma and benign epithelium. After RT, all steroid receptors were upregulated in prostatic stroma. Tumor AR expression did not change significantly. Although a positive association between AR and ER-beta expression was observed in pre-treatment prostate adenocarcinoma, it was lost after RT suggesting that these 2 steroid receptors respond differently to RT. High levels of pretreatment tumor ER-beta were associated with local recurrence after RT and decreased biochemical recurrence-free survival (p = 0.028). LNCaP cell line that expressed no ER-beta mRNA before gamma-irradiation, clearly expressed ER-beta mRNA 24 hr after 0.5 Gy and 8.0 Gy. Upregulation of all steroid receptors in the prostate stroma and upregulation of ER-beta in the tumor epithelium after RT, may represent a protective tissue response to radiation-induced tissue injury. Although stromal AR was doubled after RT, the tumor and benign epithelium expression of AR seemed resistant to change by RT. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15900599     DOI: 10.1002/ijc.21174

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

Review 1.  RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells.

Authors:  Aaron K Holley; Yong Xu; Daret K St Clair; William H St Clair
Journal:  Ann N Y Acad Sci       Date:  2010-07       Impact factor: 5.691

Review 2.  Therapeutic targeting of the prostate cancer microenvironment.

Authors:  Maria Karlou; Vassiliki Tzelepi; Eleni Efstathiou
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

Review 3.  Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.

Authors:  Murielle Mimeault; Parmender P Mehta; Ralph Hauke; Surinder K Batra
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

4.  The role of androgen receptor expression in the curative treatment of prostate cancer with radiotherapy: a pilot study.

Authors:  Filip Poelaert; Charles Van Praet; Anne-Sophie Beerens; Gert De Meerleer; Valérie Fonteyne; Piet Ost; Nicolaas Lumen
Journal:  Biomed Res Int       Date:  2015-02-22       Impact factor: 3.411

5.  Expression of estrogen receptor beta correlates with adverse prognosis in resected pancreatic adenocarcinoma.

Authors:  Hendrik Seeliger; Ioannis Pozios; Gerald Assmann; Yue Zhao; Mario H Müller; Thomas Knösel; Martin E Kreis; Christiane J Bruns
Journal:  BMC Cancer       Date:  2018-10-29       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.